Literature DB >> 29804188

Neutrophils as a Potential Source of Chitinase-3-like Protein 1 in Cystic Fibrosis.

Adèle Coriati1, Chantal Massé1, Aurélie Ménard1, Guillaume F Bouvet1, Yves Berthiaume2,3.   

Abstract

The chitinase-3-like protein 1, also known as YKL-40, is an inflammatory marker increased in blood of patients with cystic fibrosis (CF). Systemic levels of YKL-40 are increased in dysglycemic patients with CF. Our objective is to determine if YKL-40 is expressed and released by CF neutrophils. We also assessed if specific stimulus, such as glucose and lipopolysaccharide (LPS), can induce the secretion of YKL-40. Neutrophil cells of healthy adults and patients with CF were isolated. Immunostaining of whole blood and neutrophils was done. CF and healthy neutrophils were cultured with either LPS or varying concentrations of glucose. YKL-40 protein was measured using specific immunoassay ELISA. Isolated neutrophil cells from 11 patients with CF (32.3 ± 8.0 years) were compared to five age-matched healthy individuals (28.3 ± 5.5 years). Although there is a significant increase in the concentration of YKL-40 in CF neutrophils compared to healthy neutrophils (P = 0.027), the spontaneous release of YKL-40 into the media is similar in CF and healthy neutrophils. CF neutrophils stimulated with LPS or glucose do not stimulate the release of YKL-40 (P = 0.995 for glucose and P = 0.624 for LPS). CF neutrophils have higher intracellular level of YKL-40 than neutrophils from healthy volunteers, but they do not release more YKL-40 when stimulated with exogenous stimulus. These results suggest that the increased levels of circulating YKL-40 in CF patients might originate from another cellular source.

Entities:  

Keywords:  chitinase-3-like protein 1; cystic fibrosis; glucose; lipopolysaccharides; neutrophils

Mesh:

Substances:

Year:  2018        PMID: 29804188     DOI: 10.1007/s10753-018-0806-7

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  37 in total

Review 1.  Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy.

Authors:  André M Cantin; Dominik Hartl; Michael W Konstan; James F Chmiel
Journal:  J Cyst Fibros       Date:  2015-03-23       Impact factor: 5.482

2.  Plasma YKL-40 and total and disease-specific mortality in the general population.

Authors:  Julia S Johansen; Stig E Bojesen; Anne Tybjaerg-Hansen; Anne K Mylin; Paul A Price; Børge G Nordestgaard
Journal:  Clin Chem       Date:  2010-08-26       Impact factor: 8.327

3.  YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils.

Authors:  B Volck; P A Price; J S Johansen; O Sørensen; T L Benfield; H J Nielsen; J Calafat; N Borregaard
Journal:  Proc Assoc Am Physicians       Date:  1998 Jul-Aug

4.  High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality.

Authors:  J S Johansen; A N Pedersen; M Schroll; T Jørgensen; B K Pedersen; H Bruunsgaard
Journal:  Clin Exp Immunol       Date:  2007-12-06       Impact factor: 4.330

Review 5.  Liver disease in cystic fibrosis.

Authors:  Carla Colombo
Journal:  Curr Opin Pulm Med       Date:  2007-11       Impact factor: 3.155

6.  Overexpression of chitinase 3-like 1/YKL-40 in lung-specific IL-18-transgenic mice, smokers and COPD.

Authors:  Yuki Sakazaki; Tomoaki Hoshino; Satoko Takei; Masanori Sawada; Hanako Oda; Shin-ichi Takenaka; Haruki Imaoka; Kazuko Matsunaga; Toshio Ota; Yuzuru Abe; Ichiro Miki; Kiminori Fujimoto; Tomotaka Kawayama; Seiya Kato; Hisamichi Aizawa
Journal:  PLoS One       Date:  2011-09-07       Impact factor: 3.240

7.  Role of airway glucose in bacterial infections in patients with chronic obstructive pulmonary disease.

Authors:  Patrick Mallia; Jessica Webber; Simren K Gill; Maria-Belen Trujillo-Torralbo; Maria Adelaide Calderazzo; Lydia Finney; Eteri Bakhsoliani; Hugo Farne; Aran Singanayagam; Joseph Footitt; Richard Hewitt; Tatiana Kebadze; Julia Aniscenko; Vijay Padmanaban; Philip L Molyneaux; Ian M Adcock; Peter J Barnes; Kazihuro Ito; Sarah L Elkin; Onn Min Kon; William O Cookson; Miriam F Moffat; Sebastian L Johnston; John S Tregoning
Journal:  J Allergy Clin Immunol       Date:  2018-01-05       Impact factor: 10.793

Review 8.  YKL-40--an emerging biomarker in cardiovascular disease and diabetes.

Authors:  Camilla N Rathcke; Henrik Vestergaard
Journal:  Cardiovasc Diabetol       Date:  2009-11-23       Impact factor: 9.951

9.  Plasma YKL-40: a BMI-independent marker of type 2 diabetes.

Authors:  Anders R Nielsen; Christian Erikstrup; Julia S Johansen; Christian P Fischer; Peter Plomgaard; Rikke Krogh-Madsen; Sarah Taudorf; Birgitte Lindegaard; Bente K Pedersen
Journal:  Diabetes       Date:  2008-07-23       Impact factor: 9.461

10.  Neutrophil microparticle production and inflammasome activation by hyperglycemia due to cytoskeletal instability.

Authors:  Stephen R Thom; Veena M Bhopale; Kevin Yu; Weiliang Huang; Maureen A Kane; David J Margolis
Journal:  J Biol Chem       Date:  2017-09-25       Impact factor: 5.157

View more
  1 in total

1.  Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy.

Authors:  Pei-Shan Yang; Min-Hua Yu; Ya-Chin Hou; Chih-Peng Chang; Shao-Chieh Lin; I-Ying Kuo; Pei-Chia Su; Hung-Chi Cheng; Wu-Chou Su; Yan-Shen Shan; Yi-Ching Wang
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.